Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Breast cancer, early stage

2229 - Phase III evaluating the addition of fulvestrant (F) to Anastrozol (A) as adjuvant therapy in postmenopausal women with hormone receptor positive HER2 negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study


08 Sep 2017


Breast cancer, early stage


Cytotoxic Therapy;  Breast Cancer;  Prostate Cancer


Manuel Ruíz-Borrego


Annals of Oncology (2017) 28 (suppl_5): v43-v67. 10.1093/annonc/mdx362


M. Ruíz-Borrego1, M. Martin Jimenez2, A. Ruiz3, A. Lluch4, M. Ramos5, J. Cruz Jurado6, J.M. Baena-Canada7, B. Cirauqui8, A. Rodriguez-Lescure9, E. Alba Conejo10, N. Martínez Jañez11, M. Muñoz12, S. Antolin13, I. Álvarez López14, S. Del Barco15, L. Garcia-Estevez16, J..I. Chacon Lopez-Muniz17, A. Anton Torres18, E. Carrasco19

Author affiliations

  • 1 Oncologia, Hospital Virgen del Rocío, - - Sevilla/ES
  • 2 Medical Oncology, Hospital General Universitario Gregorio Marañon, GEICAM, CIBERONC., 28009 - Madrid/ES
  • 3 Clinical Oncology, Instituto Valenciano de Oncología, Valencia/ES
  • 4 Medical Oncology  , Hospital Clinico Universitario de Valencia, 46010 - Valencia/ES
  • 5 Medical Oncology, Centro Oncologico de Galicia, A Coruña/ES
  • 6 Clinical Oncology, Hospital Universitario de Canarias, 38320 - San Cristobal de la Laguna/ES
  • 7 Clincal Oncology, H. U. Puerta del Mar, 11009 - Cadiz/ES
  • 8 Clincal Oncology, Institut Català d’Oncologia Badalona, Hospital Universitario Germans Trias i Pujol, Badalona/ES
  • 9 Medical Oncology, H G U de Elche, Elche Alicante/ES
  • 10 Clinical Oncology, Hospital Universitario Virgen de la Victoria, GEICAM, CIBERONC, 29010 - Malaga/ES
  • 11 Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid/ES
  • 12 Clinical Oncology, 12H Clinic i Provincial de Barcelona, Barcelona/ES
  • 13 Clinical Oncology, 13Complejo Hospitalario U A Coruña, Coruña/ES
  • 14 Medical Oncology, Hospital Universitario Donostia, 20014 - Donostia/ES
  • 15 Clinical Oncology, 15Instituto Catalan de Oncologia de Girona, Girona/ES
  • 16 Medical Oncology, Centro Integral Oncologico Clara Campal, Madrid/ES
  • 17 Clinical Oncology, Hospital Virgen de la Salud, 49004 - Toledo/ES
  • 18 Clinical Oncology, Hospital Miguel Servet, 50009 - Zaragoza/ES
  • 19 Scientific Director, GEICAM, Madrid/ES


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2229


F is a selective estrogen receptor degrader for HR+ advanced breast cancer patients (pts). We designed this trial to compare A vs. A in combination with F (A+F) to address the hypothesis that a complete estrogen blockade can prevent resistance to aromatase inhibitors in the adjuvant setting.


This was a multicenter, open label, phase III study in which HR+/HER2- EBC postmenopausal pts were randomized 1:1 to A for 5 years (y) or A+F (A concurrently with F 250mg/4 weeks for 3y followed by 2y of A). Pts were stratified for prior chemotherapy (yes/no); number of positive lymph-nodes (0/1-3/≥4); HR status (both positive/one positive) and site. Primary objective was disease-free survival (DFS). To detect an absolute 5-y DFS increase of 3% (90% A, 93% A+F) a sample size of 2716 evaluable patients was required. On 2010, when the negative results of the FACT trial were made available, the financer decided to stop the study support after the inclusion of 872 pts.


From January 2008 to June 2010, 437 pts were randomized to A and 435 to A+F. Pts characteristics were well balanced between arms; median age was 62 y (40-86), 46.9% were N0, 89.5% ER+/PgR+ and 68.2% had received prior chemotherapy. Treatment was completed as planned by 72.5% and 48.5% of A and A+F pts. Median relative dose intensity was 99% for A (both arms) and 81% for F. Most relevant G2-3 toxicities (>5% in either arm) with A vs. A+F were hypertension (13.2%; 9.9%), fatigue (5.2%; 11.8%), LDL-Cholesterol increase (9.4%; 5.3%), osteoporosis (5.5%; 6.9%) and musculoskeletal bone/joint pain (26.3%; 29.4%). After a median follow-up of 6.3y, the proportion of pts disease free at 5y was 90.99% (A 90.77%, A+F 91.25%, D = 0.48%, p = 0.357); 9.4% had BC relapse (A 10.5%; A+F 8.3%, D = 2.2%) and 4.3% had secondary tumors (A 3.9%; A+F 4.6%). Survival and breast cancer-specific survival were not reached.


The GEICAM/2006-10 study failed to demonstrate a statistically significant increase in DFS adding F to A as adjuvant therapy, though no formal conclusion can be extracted from this trial due to the F administered dose and the actual trial sample size.

Clinical trial identification


Legal entity responsible for the study

GEICAM Spanish Breast Cancer Group


Astra Zeneca Astra Zeneca Astra Zeneca Astra Zeneca


M. Martin Jimenez: Speaker honoraria and AstraZeneca advisory boards participation. J.M. Baena-Canada: Consulting/relationship advice for AstraZeneca. M. Muñoz: Advisory Board from AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.